636 related articles for article (PubMed ID: 27692977)
41. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Moss RB
Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
[TBL] [Abstract][Full Text] [Related]
42. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
Fjaellegaard K; Sin MD; Browatzki A; Ulrik CS
Chron Respir Dis; 2017 May; 14(2):174-186. PubMed ID: 27507832
[TBL] [Abstract][Full Text] [Related]
43. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
Dhand R
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic Approach of Chronic
Varannai O; Gede N; Juhász MF; Szakács Z; Dembrovszky F; Németh D; Hegyi P; Párniczky A
Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34438986
[No Abstract] [Full Text] [Related]
45. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
Harrison MJ; McCarthy M; Fleming C; Hickey C; Shortt C; Eustace JA; Murphy DM; Plant BJ
J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
[TBL] [Abstract][Full Text] [Related]
46. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
[TBL] [Abstract][Full Text] [Related]
47. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
48. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.
Plant BJ; Downey DG; Eustace JA; Gunaratnam C; Haworth CS; Jones AM; McKone EF; Peckham DG; Ketchell RI; Bilton D
J Cyst Fibros; 2017 Nov; 16(6):695-701. PubMed ID: 28392014
[TBL] [Abstract][Full Text] [Related]
49. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
[TBL] [Abstract][Full Text] [Related]
50. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
51. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
[TBL] [Abstract][Full Text] [Related]
52. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
[TBL] [Abstract][Full Text] [Related]
54. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
55. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
56. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
Dasenbrook EC; Konstan MW; VanDevanter DR
J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
[TBL] [Abstract][Full Text] [Related]
57. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
58. Administration of aerosolized antibiotics in cystic fibrosis patients.
Moss RB
Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
[TBL] [Abstract][Full Text] [Related]
59. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
[TBL] [Abstract][Full Text] [Related]
60. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
